Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes

BMC Complementary and Alternative Medicine

Volumn 10, Issue , 2010, Pages

  Nerurkar, Pratibha V ^a   Lee, Yun Kung ^a   Nerurkar, Vivek R ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; GLYCEROL; MESSENGER RNA; MOMORDICA CHARANTIA EXTRACT; PERILIPIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESISTIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; PHOSPHOPROTEIN; PLANT MEDICINAL PRODUCT; TRANSCRIPTION FACTOR;

ADIPOCYTE; ARTICLE; CELL ASSAY; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID STORAGE; LIPOLYSIS; MOMORDICA CHARANTIA; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADIPOGENESIS; CYTOLOGY; DRUG EFFECT; FRUIT; GENETICS; LIPID METABOLISM; LIPOGENESIS; METABOLISM;

ADIPOCYTES; ADIPOGENESIS; CELL DIFFERENTIATION; FRUIT; HUMANS; LIPID METABOLISM; LIPOGENESIS; MOMORDICA CHARANTIA; PHOSPHOPROTEINS; PLANT PREPARATIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 77953931932     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-10-34     Document Type: Article

References (64)

1. Low S, Chin MC, Deurenberg-Yap M. Review on epidemic of obesity. Ann Acad Med Singapore 2009, 38:57-59.
2. Scheen AJ. Antiobesity pharmacotherapy in the management of type 2 diabetes. P.J.L.: Diabetes Metab Res Rev 2000, 16:114-124.
3. Adipocyte Biology. 4th International Conference on Nutrition and HIV infection and the 2nd European Workshop on Lipodystrophy; April, 19-21; Cannes, France 2001,
4. Gregoire FM. Adipocyte differentiation: From fibroblast to endocrine cell. Exp Biol Med (Maywood) 2001, 226:997-1002.
5. Wakabayashi K, Okamura M, Tsutsumi S, Nishikawa NS, Tanaka T, Sakakibara I, Kitakami J, Ihara S, Hashimoto Y, Hamakubo T, et al. The peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha heterodimer targets the histone modification enzyme PR-Set7/Setd8 gene and regulates adipogenesis through a positive feedback loop. Mol Cell Biol 2009, 29:3544-3555. 10.1128/MCB.01856-08, 2698772, 19414603.
6. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008, 77:289-312. 10.1146/annurev.biochem.77.061307.091829, 18518822.
7. Vernochet C, Peres SB, Davis KE, McDonald ME, Qiang L, Wang H, Scherer PE, Farmer SR. C/EBPα and the corepressors CtBP1/2 regulate repression of select visceral white adipose genes during the induction of the brown phenotype in white adipocytes by PPAR" agonists. Mol Cell Biol 2009, doi:10.1128/MCB.01899-08, 2725706, 19564408.
8. Inoue J, Kumagai H, Terada T, Maeda M, Shimizu M, Sato R. Proteolytic activation of SREBPs during adipocyte differentiation. Biochem Biophys Res Commun 2001, 283:1157-1161. 10.1006/bbrc.2001.4915, 11355894.
9. Kim JB, Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev 1996, 10:1096-1107. 10.1101/gad.10.9.1096, 8654925.
10. Tansey JT, Sztalryd C, Gruia-Gray J, Roush DL, Zee JV, Gavrilova O, Reitman ML, Deng CX, Li C, Kimmel AR, Londos C. Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. Proc Natl Acad Sci USA 2001, 98:6494-6499. 10.1073/pnas.101042998, 33496, 11371650.
11. Tansey JT, Sztalryd C, Hlavin EM, Kimmel AR, Londos C. The central role of perilipin a in lipid metabolism and adipocyte lipolysis. IUBMB Life 2004, 56:379-385. 10.1080/15216540400009968, 15545214.
12. Ye ZW, Wu XM, Jiang JG. Expression changes of angiotensin II pathways and bioactive mediators during human preadipocytes-visceral differentiation. Metabolism 2009,
13. Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, Enders GH, Silberg DG, Wen X, Wu GD, Lazar MA. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001, 98:502-506. 10.1073/pnas.98.2.502, 14616, 11209052.
14. Sheperd TM. Effective management of obesity. The J Family Practice 2003, 52:1-13.
15. Isidro ML, Cordido F. Drug treatment of obesity: established and emerging therapies. Mini Rev Med Chem 2009, 9:664-673. 10.2174/138955709788452739, 19519492.
16. Tsai AG, Wadden TA. Treatment of Obesity in Primary Care Practice in the United States: A Systematic Review. J Gen Intern Med 2009,
17. Baker MK, Byrne TK, Feldmann ME. Surgical treatment of obesity. Prim Care 2009, 36:417-427.
18. Bloomgarden ZT. Obesity: mediators and treatment approaches. Diabetes Care 2009, 32:e48-52. 10.2337/dc09-zb05, 19407063.
19. Boissonneault GA. Obesity: the current treatment protocols. JAAPA 2009, 22(16):18-19.
20. Shewmake RA, Huntington MK. Nutritional treatment of obesity. Prim Care 2009, 36:357-377.
21. Hasani-Ranjbar S, Nayebi N, Larijani B, Abdollahi M. A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity. World J Gastroenterol 2009, 15:3073-3085. 10.3748/wjg.15.3073, 2705729, 19575486.
22. Grover JK, Yadav S, Vats V. Medicinal plants of India with anti-diabetic potential. J Ethnopharmacol 2002, 81:81-100. 10.1016/S0378-8741(02)00059-4, 12020931.
23. Chen Q, Chan LLY, Li ETS. Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high diet. J Nutr 2003, 133:1088-1093.
24. Chen Q, Li ET. Reduced adiposity in bitter melon (Momordica charantia) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines. Br J Nutr 2005, 93:747-754. 10.1079/BJN20051388, 15975176.
25. Huang HL, Hong YW, Wong YH, Chen YN, Chyuan JH, Huang CJ, Chao PM. Bitter melon (Momordica charantia L.) inhibits adipocyte hypertrophy and down regulates lipogenic gene expression in adipose tissue of diet-induced obese rats. Br J Nutr 2008, 99:230-239. 10.1017/S0007114507793947, 17651527.
26. Nerurkar PV, Lee YK, Motosue M, Adeli K, Nerurkar VR. Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. Br J Nutr 2008, 100:751-759. 10.1017/S0007114508937430, 18321395.
27. Nerurkar PV, Pearson L, Efird JT, Adeli K, Theriault AG, Nerurkar VR. Microsomal triglyceride transfer protein gene expression and ApoB secretion are inhibited by bitter melon in HepG2 cells. J Nutr 2005, 135:702-706.
28. Nerurkar PV, Dragull K, Tang CS. In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones. Toxicol Sci 2004, 79:106-111. 10.1093/toxsci/kfh067, 14737001.
29. Shi Y, Liu Y, Murdin A, Raudonikiene-Mancevski A, Ayach B, Yu Z, Fantus G, Liu P. Chlamydophila pneumoniae inhibits differentiation of progenitor adipose cells and impairs insulin signaling. J Infect Dis 2008, 197:439-448. 10.1086/525045, 18199028.
30. Chaturvedi P. Role of Momordica charantia in maintaining the normal levels of lipids and glucose in diabetic rats fed a high-fat and low-carbohydrate diet. Br J Biomed Sci 2005, 62:124-126.
31. Tan MJ, Ye JM, Turner N, Hohnen-Behrens C, Ke CQ, Tang CP, Chen T, Weiss HC, Gesing ER, Rowland A, et al. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol 2008, 15:263-273. 10.1016/j.chembiol.2008.01.013, 18355726.
32. Sridhar MG, Vinayagamoorthi R, Arul Suyambunathan V, Bobby Z, Selvaraj N. Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. Br J Nutr 2008, 99:806-812. 10.1017/S000711450783176X, 17942003.
33. Chan LL, Chen Q, Go AG, Lam EK, Li ET. Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression. J Nutr 2005, 135:2517-2523.
34. Rayalama S, Della-Feraa MA, Bailea CA. Phytochemicals and regulation of the adipocyte life cycle. J Nurtitional Biochemistry 2008, 19:717-726.
35. Umek RM, Friedman AD, Mcknight SL. CCAAT-enhancer binding protein: a component of a differentiation switch. Science 1991, 251:288-292. 10.1126/science.1987644, 1987644.
36. Huang C, Zhang Y, Gong Z, Sheng X, Li Z, Zhang W, Qin Y. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARγ pathway. Biochem Biophy Res Commun 2006, 348:571-578.
37. Vidhya S, Mohan V. Rosiglitazone--useful drug but has side effects. J Assoc Physicians India 2002, 50:615.
38. Christensen KB, Minet A, Svenstrup H, Grevsen K, Zhang H, Schrader E, Rimbach G, Wein S, Wolffram S, Kristiansen K, Christensen LP. Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake. Phytother Res 2009,
39. Freise C, Erben U, Neuman U, Kim K, Zeitz M, Somasundaram R, Ruehl M. An active extract of Lindera obtusiloba inhibits adipogenesis via sustained Wnt signaling and exerts anti-inflammatory effects in the 3T3-L1 preadipocytes. J Nutr Biochem
40. Hsuy S-C, Huang C-J. Reduced fat mass in rats fed a high oleic acid-rich safflower oil diet is associated with changes in expression of hepatic PPARα and adipose SREBP-1c-regulated genes. J Nutr 2006, 136:1779-1785.
41. Roffey BW, Atwal AS, Johns T, Kubow S. Water extracts from Momordica charantia increase glucose uptake and adiponectin secretion in 3T3-L1 adipose cells. J Ethnopharmacol 2007, 112:77-84. 10.1016/j.jep.2007.02.003, 17363205.
42. Shih CC, Lin CH, Lin WL. Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet. Diabetes Res Clin Pract 2008, 81:134-143. 10.1016/j.diabres.2008.04.023, 18550200.
43. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, Saruta T. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003, 11:997-1001. 10.1038/oby.2003.137, 12917505.
44. McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, Crocker J, Barnett AH, Kumar S. Increased resistin gene and protein expression in human abdominal adipose tissue. 87:2407. J Clin Endocrinol Metab 2002, 87:2407-2414. 10.1210/jc.87.5.2407, 11994397.
45. Valsamakis G, McTernan PG, Chetty R, Al Daghri N, Field A, Hanif W, Barnett AH, Kumar S. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004, 53:430-434. 10.1016/j.metabol.2003.11.022, 15045687.
46. Garcia A, Sekowski A, Subramanian V, Brasaemle D. The central domain is required to target and anchor perilipin A to lipid droplets. J Biol Chem 2003, 278:625-635. 10.1074/jbc.M206602200, 12407111.
47. Souza S, Palmer H, Kang Y, Yamamoto M, Muliro K, Paulson K, Greenberg A. TNF-alpha induction of lipolysis is mediated through activation of the extracellular signal related kinase pathway in 3T3-L1 adipocytes. J Cell Biochem 2003, 89:1077-1086. 10.1002/jcb.10565, 12898507.
48. Zhang H, Halbleib M, Ahmad F, Manganiello VC, Greenberg A. Tumor necrosis factor-a stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 2002, 51:2929-2935. 10.2337/diabetes.51.10.2929, 12351429.
49. Ryden M, Arvidsson E, Blomqvist L, Perbeck L, Dicker A, Arner P. Targets for TNF-a-induced lipolysis in human adipocytes. Biochem Biophys Res Commun 2004, 318:168-175. 10.1016/j.bbrc.2004.04.010, 15110769.
50. Khanna P, Jain SC, Panagariya A, Dixit VP. Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod 1981, 44:648-655. 10.1021/np50018a002, 7334382.
51. Jantan I, Rafi IA, Jalil J. Platelet-activating factor (PAF) receptor-binding antagonist activity of Malaysian medicinal plants. Phytomedicine 2005, 12:88-92. 10.1016/j.phymed.2003.06.006, 15693713.
52. Anila L, Vijayalakshmi NR. Beneficial effects of flavonoids from Sesamum indicum, Emblica officinalis and Momordica charantia. Phytother Res 2000, 14:592-595. 10.1002/1099-1573(200012)14:8<592::AID-PTR772>3.0.CO;2-#, 11113993.
53. Islam S, Jalaluddin M, Hettiarachchy NS. Physiological Functions of bitter melon varieties (Momordica charantia L,) in relation to polyphenolic contents. HortScience 2008, 43:1223.
54. Park HJ, Yang JY, Ambati S, Della-Fera MA, Hausman DB, Rayalam S, Baile CA. Combined effects of genistein, quercetin, and resveratrol in human and 3T3-L1 adipocytes. J Med Food 2008, 11:773-783. 10.1089/jmf.2008.0077, 19053873.
55. Yang JY, Della-Fera MA, Rayalam S, Ambati S, Hartzell DL, Park HJ, Baile CA. Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci 2008, 82:1032-1039. 10.1016/j.lfs.2008.03.003, 18433793.
56. Hsu CL, Huang SL, Yen GC. Inhibitory effect of phenolic acids on the proliferation of 3T3-L1 preadipocytes in relation to their antioxidant activity. J Agric Food Chem 2006, 54:4191-4197. 10.1021/jf0609882, 16756346.
57. Harinantenaina L, Tanaka M, Takaoka S, Oda M, Mogami O, Uchida M, Asakawa Y. Momordica charantia constituents and antidiabetic screening of the isolated major compounds. Chem Pharm Bull (Tokyo) 2006, 54:1017-1021. 10.1248/cpb.54.1017, 16819222.
58. Welihinda J, Karunanayake EH, Sheriff MH, Jayasinghe KS. Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J Ethnopharmacol 1986, 17:277-282. 10.1016/0378-8741(86)90116-9, 3807390.
59. Leatherdale BA, Panesan RK, Singh G, Atkins TW, Bailey CJ, Bignell AH. Improvement in glucose tolerance due to Momordica charantia (karela). Br Med J (Clin Res Ed) 1981, 282:1823-1824. 10.1136/bmj.282.6279.1823, 1506397, 6786635.
60. Srivastava Y, Venkatakrishna-Bhatt H, Verma Y, et al. Antidiabetic and adaptogenic properties of Momordica charantia extract. An experimental and clinical evaluation. Phytother Res 1993, 7:285-289.
61. Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 2003, 60:356-359.
62. Tuekpe MK, Todoriki H, Sasaki S, Zheng KC, Ariizumi M. Potassium excretion in healthy Japanese women was increased by a dietary intervention utilizing home-parcel delivery of Okinawan vegetables. Hypertens Res 2006, 29:389-396. 10.1291/hypres.29.389, 16940700.
63. Ahmed N, Hassan MR, Halder H, Bennoor KS. Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients. Bangladesh Med Res Counc Bull 1999, 25:11-13.
64. Welihinda J, Karunanayake EH. Extra-pancreatic effects of Momordica charantia in rats. J Ethnopharmacol 1986, 17:247-255. 10.1016/0378-8741(86)90112-1, 3807387.